within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01E_SulfonamidesAndTrimethoprim.J01EA02_Brodimoprim;

model Brodimoprim
  extends Pharmacolibrary.Drugs.ATC.J.J01EA02;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J01EA02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Brodimoprim is a synthetic diaminopyrimidine antibacterial agent related to trimethoprim. It acts as a selective bacterial dihydrofolate reductase inhibitor, used historically in the treatment of urinary tract and respiratory infections. It is not widely used or approved for clinical use today.</p><h4>Pharmacokinetics</h4><p>Reported pharmacokinetic parameters in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Weidekamm, E (1993). Pharmacokinetics of brodimoprim. <i>Journal of chemotherapy (Florence, Italy)</i> 5(6) 475–479. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8195840/&quot;>https://pubmed.ncbi.nlm.nih.gov/8195840</a></p></li><li><p>Braga, PC, et al., &amp; Reggio, S (1996). Penetration of brodimoprim into human neutrophils and intracellular activity. <i>Antimicrobial agents and chemotherapy</i> 40(10) 2392–2398. DOI:<a href=&quot;https://doi.org/10.1128/AAC.40.10.2392&quot;>10.1128/AAC.40.10.2392</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8891150/&quot;>https://pubmed.ncbi.nlm.nih.gov/8891150</a></p></li><li><p>Stockis, A, et al., &amp; Rosillon, D (1993). Pharmacokinetics of brodimoprim in special populations. <i>Journal of chemotherapy (Florence, Italy)</i> 5(6) 480–487. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8195841/&quot;>https://pubmed.ncbi.nlm.nih.gov/8195841</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Brodimoprim;
